Articles

• Good News for Anti-VEGF Therapy

  By Robert L. Avery, MD; and Allen C. Ho, MD

• Medical Update

  By David Boyer, MD

• Ophthalmologists Remember Judah Folkman, MD

  1933-2008

• New Innovations in AMD Therapy May Be Promising

  By Samir Patel, MD

• Navigating Contract Negotiation

  By David Eichenbaum, MD

• Retina Comes of Age in the ASC Setting

  The time has come to integrate retinal procedures and surgical efficiencies.

  By Pravin U. Dugel, MD

• Collaborative Retina in Latin America: How Did We Get Here?

  By Fernando Arevalo, MD, FACS

• Combined 25/20-gauge Vitreoretinal Surgery: A New 25/20-gauge Plug

  By Ronald C. Gentile, MD

• Mechanisms Behind Disease: DME

  Current knowledge of the pathophysiology and pathobiochemistry guides treatment

  By Albert J. Augustin, MD, and Stanislao Rizzo, MD

• Transconjunctival 25-gauge Surgery for Diabetic Traction Retinal Detachment

  Results with sutureless technique compare well with 20-gauge.

  By John O. Mason III, MD

• Intravitreal Bevacizumab in the Surgical Treatment of Proliferative Diabetic Retinopathy

  Given at the time of surgery, the anti-VEGF agent reduces intraoperative and postoperative bleeding.

  By Robert L. Avery, MD

• Avoid Blind Spots in Surgery While Utilizing Less Energy

  Principals from the "green" movement are applied to endoillumination.

  By Michael Bennett, MD; and Dante Pieramici, MD

• Biplanar 5°/30° Insertion Technique

  The one-step technique, carefully executed, ensures watertight 23-gauge wound closure.

  By John S. Pollack, MD

• RAD for Central Retinal Vein Occlusion

  Novel venous circulation is achieved via creation of multiple venous anastomotic sites.

  By Calvin Grant, MD

• Retinal Detachment Laser Prophylaxis

  Ora secunda cerclage (OSC): Creating a second ora.

  By Robert Morris, MD; C. Douglas Witherspoon, MD; Ferenc Kuhn, MD, PhD; and Mathew Sapp, MD

• Pegaptanib Treatment for CRVO

  Significant improvement was seen on OCT among patients with macular edema following CRVO.

  By Karl G. Csaky, MD, PhD

• MARINA and ANCHOR: An Overview of the Safety Data

  Combined 2-year analysis increases confidence in ranibizumab.

  By Carl Regillo, MD

• Rate of Endophthalmitis After Anti-VEGF Intravitreal Injection

  The rate of endophthalmitis was low in a series of almost 20,000 intravitreal injections of anti-VEGF agents.

  By Andrew A. Moshfeghi, MD

• Case Report

  Retinal vasoproliferative tumor with associated cystoid macular edema treated with cryotherapy and intravitreal triamcinolone.

  By Carlos Bianciotto, MD; and Carol L. Shields, MD

• CONFERENCE CALENDAR

• 5 Questions With David W. Parke II, MD

  David W. Parke II, MD, was recently named President of the American Academy of Ophthalmology.

  By David W. Parke II, MD